Expectant management with selective delayed intervention for favorable-risk prostate cancer

被引：0
|
作者：
Klotz, L [1 ]
机构：
[1] Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada
来源：
PROSTATE AND RENAL CANCER, BENIGN PROSTATIC HYPERPLASIA, ERECTILE DYSFUNCTION AND BASIC RESEARCH: AND UPDATE | 2003年
关键词：
D O I：
暂无
中图分类号：
R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
摘要：
引用
收藏
页码：274 / 279
页数：6
相关论文
共 50 条
  • [21] COMPARISON OF PATHOLOGIC OUTCOMES IN MEN WITH FAVORABLE-RISK PROSTATE CANCER UNDERGOING DELAYED SURGERY AFTER ACTIVE SURVEILLANCE VERSUS IMMEDIATE SURGERY
    Tosoian, Jeffrey
    Sundi, Debasish
    Trock, Bruce
    Landis, Patricia
    Epstein, Jonathan
    Schaeffer, Edward
    Mamawala, Mufaddal
    Carter, H. Ballentine
    JOURNAL OF UROLOGY, 2015, 193 (04): : E757 - E758
  • [22] A PROSPECTIVE, LONGITUDINAL ACTIVE SURVEILLANCE PROGRAM FOR FAVORABLE-RISK PROSTATE CANCER: LONG TERM OUTCOMES
    Tosoian, Jeffrey
    Mamawala, Mufaddal
    Epstein, Jonathan
    Landis, Patricia
    Wolf, Sacha
    Trock, Bruce
    Carter, H. Ballentine
    JOURNAL OF UROLOGY, 2015, 193 (04): : E147 - E147
  • [23] ACTIVE SURVEILLANCE FOR FAVORABLE-RISK PROSTATE CANCER IN AFRICAN CARIBBEAN MEN: RESULTS OF A PROSPECTIVE STUDY
    Meunier, Matthias
    Eyraud, Remi
    Senechal, Cedric
    Gourtaud, Gilles
    Roux, Virginie
    Lanchon, Cecilia
    Brureau, Laurent
    Blanchet, Pascal
    JOURNAL OF UROLOGY, 2017, 197 (04): : E561 - E562
  • [24] Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT
    Mihalcik, Stephen A.
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    EUROPEAN UROLOGY FOCUS, 2018, 4 (01): : 64 - 67
  • [25] OncotypeDx genomic scores independent of disease volume in men with favorable-risk prostate cancer.
    Grimberg, Dominic C.
    Nyame, Yaw A.
    Greene, Daniel J.
    Gupta, Karishma
    Berglund, Ryan Kent
    Gong, Michael C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [26] Comorbidity and the receipt of curative therapy for favorable-risk prostate cancer prior to and following the publication of PIVOT
    Mihalcik, Stephen A.
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian Joseph
    D'Amico, Anthony V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [27] A Roadmap for Improving the Management of Favorable Risk Prostate Cancer
    Auffenberg, Gregory B.
    Lane, Brian R.
    Linsell, Susan
    Brachulis, Andrew
    Ye, Zaojun
    Rakic, Nikola
    Montie, James
    Miller, David C.
    Cher, Michael L.
    JOURNAL OF UROLOGY, 2017, 198 (06): : 1221 - 1223
  • [28] Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome
    Swami, Nishwant
    Nguyen, Tiffany
    Ogobuiro, Ifeanyichukwu
    Abramowitz, Matthew
    Chipidza, Fallon
    Davicioni, Elai
    Meiyappan, Karthik
    Dal Pra, Alan
    Nguyen, Paul L.
    Pollack, Alan
    Punnen, Sanoj
    Mahal, Brandon A.
    Alshalalfa, Mohammed
    CLINICAL GENITOURINARY CANCER, 2023, 21 (01) : 76 - 83
  • [29] HIGH-DOSE-RATE BRACHYTHERAPY AS A MONOTHERAPY FOR FAVORABLE-RISK PROSTATE CANCER: A PHASE II TRIAL
    Barkati, Maroie
    Williams, Scott G.
    Foroudi, Farshad
    Tai, Keen Hun
    Chander, Sarat
    van Dyk, Sylvia
    See, Andrew
    Duchesne, Gillian M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (05): : 1889 - 1896
  • [30] Association Between Early Confirmatory Testing and the Adoption of Active Surveillance for Men With Favorable-risk Prostate Cancer
    Kaye, Deborah R.
    Qi, Ji
    Morgan, Todd M.
    Linsell, Susan
    Lane, Brian R.
    Montie, James E.
    Cher, Michael L.
    Miller, David C.
    UROLOGY, 2018, 118 : 127 - 133
12345